HomeInsightsStock Comparison

Aarti Pharmalabs Ltd vs Speciality Medicines Ltd Stock Comparison

Aarti Pharmalabs Ltd vs Speciality Medicines Ltd Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

  • The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 771.9 as of 05 May 15:30 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 24.9 on March 2025 . This represents a CAGR of 24.51% over 3 yearsThe P/E Ratio of Speciality Medicines Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 6784 crore on March 2025 . This represents a CAGR of 39.69% over 3 yearsThe Market Cap of Speciality Medicines Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 436.83 crore as compare to the Sep '25 revenue of ₹ 418.39 crore. This represent the growth of 4.41% The revenue of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 104.07 crore as compare to the Sep '25 ebitda of ₹ 74.13 crore. This represent the growth of 40.39% The ebitda of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 47.96 crore over 7 quarters. This represents a CAGR of -7.96% The net profit of Speciality Medicines Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Speciality Medicines Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aarti Pharmalabs Ltd

  • Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
  • The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
  • Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
  • It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Speciality Medicines Ltd

  • Speciality Medicines Limited was originally incorporated as 'Speciality Medicines Private Limited' as a Private Limited Company, dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre.
  • Later on, the status was converted to Public Limited and the name of the Company was changed to 'Speciality Medicines Limited' and a fresh Certificate of Incorporation dated June 25, 2024 was issued to the Company by Registrar of Companies. The Company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market.
  • The Company has presence over 35 countries. The Company deal in Specialty pharmaceuticals finished formulations Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet, Suspension and Tablet.

FAQs for the comparison of Aarti Pharmalabs Ltd and Speciality Medicines Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Speciality Medicines Ltd?

Market cap of Aarti Pharmalabs Ltd is 7,304 Cr while Market cap of Speciality Medicines Ltd is 275 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Speciality Medicines Ltd?

The stock performance of Aarti Pharmalabs Ltd and Speciality Medicines Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Speciality Medicines Ltd?

As of May 5, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹805.7. On the other hand, Speciality Medicines Ltd stock price is INR ₹313.95.

How do dividend payouts of Aarti Pharmalabs Ltd and Speciality Medicines Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Speciality Medicines Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions